Overview

• Cue Biopharma has priced an underwritten public offering to raise approximately $20 million, expected to close on or around April 16, 2025.
• The offering includes 13,530,780 shares of common stock and pre-funded warrants, with accompanying stock warrants exercisable for up to five years.
• Oppenheimer & Co. Inc. is managing the offering as the sole book-runner, with Newbridge Securities Corporation acting as co-manager.
• The company will host a business update conference call and webcast on April 15, 2025, at 4:30 p.m. ET to provide operational insights to investors.
• Funds raised will support Cue Biopharma's development of novel injectable biologics targeting disease-specific T cells for cancer and autoimmune diseases.